aTyr Pharma (NASDAQ:ATYR) Trading Down 2.1% – Should You Sell?

aTyr Pharma, Inc. (NASDAQ:ATYR) shares were down 2.1% during mid-day trading on Tuesday . The stock traded as low as $0.96 and last traded at $0.9888. Approximately 1,333,916 shares traded hands during trading, a decline of 52% from the average daily volume of 2,784,171 shares. The stock had previously closed at $1.01.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of aTyr Pharma in a report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $25.67.

aTyr Pharma Stock Down 2.1%

The company has a 50 day simple moving average of $0.80 and a two-hundred day simple moving average of $1.62. The company has a market capitalization of $96.89 million, a P/E ratio of -1.19 and a beta of 0.59.

Institutional Trading of aTyr Pharma

A number of institutional investors have recently bought and sold shares of ATYR. Profund Advisors LLC bought a new position in aTyr Pharma during the third quarter valued at $27,000. California State Teachers Retirement System purchased a new position in shares of aTyr Pharma during the 2nd quarter worth about $28,000. ADAR1 Capital Management LLC grew its holdings in aTyr Pharma by 35.9% during the 4th quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock valued at $40,000 after purchasing an additional 13,385 shares during the last quarter. Kingswood Wealth Advisors LLC bought a new position in aTyr Pharma during the 4th quarter valued at about $41,000. Finally, Ameritas Investment Partners Inc. purchased a new stake in aTyr Pharma in the 2nd quarter worth about $45,000. 61.72% of the stock is currently owned by institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.